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Abstract
Human mesenchymal stem cells are an attractive cell source for tissue engineering and regenerative medicine
applications, especially because of their differentiation potential toward the mesenchymal lineage. Furthermore,
this cell type participates in the regeneration of tissue damage and plays an important role in immunity. Similarly,
chitinase-like proteins have been proposed to aid in tissue remodeling, inflammation, and differentiation pro-
cesses. The chitinase-like protein YKL-40 in particular is indicated in preventing damage to the extracellular
matrix in response to proinflammatory cytokines, even though its biological function remains speculative.
Finally, interleukin (IL)-6, a pleiotropic acute phase protein, participates in the regulation of bone turnover
and immunoregulation. The physiological role of IL-6 in bone homeostasis is complex, exerting different effects
on osteoblasts and osteoclasts depending on their differentiation stage. The aim of this study was to determine the
effect of recombinant human IL-6 (5 ng/mL) on YKL-40 expression and osteogenic differentiation of human mes-
enchymal stem cells. Recombinant human IL-6 induced a donor-dependent change in mineralization and signif-
icantly promoted YKL-40 protein secretion. However, YKL-40 gene expression remained unaffected, and no
statistically significant differences in the expression of osteogenic marker genes could be observed.
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Introduction
Mesenchymal stem cells (MSCs) are multipotentprogenitor cells, residing as a heterogeneous cell pop-
ulation in the bone marrow stroma, adipose tissue, umbilical
cord blood, and other tissues.1 MSCs participate in the regen-
eration of tissue damage by migrating to sites of inflam-
mation in response to damage-associated chemokines and
cytokines, and they attract immune cells to the location of in-
jury.2 In addition, MSCs play an important role in immunity
and can modulate immune responses by cell contact–dependent
mechanisms and secretion of cytokines and growth factors,
affecting regeneration and inflammation at the sites of tissue
injury.3 Osteoblasts are the major bone-forming cells and
originate from MSCs via tightly regulated expression of
bone-specific transcription factors and matrix proteins.4
The mechanism of osteogenic differentiation can be di-
vided into two stages: initiation and maturation phases.5 Dur-
ing initiation of osteogenic differentiation, cells slowly
proliferate, express several osteogenic marker genes, and se-
crete collagen type I, which is the main structural component
of bone extracellular matrix (ECM).6 Mineralization of
the matrix by deposition of calcium phosphate substituted
hydroxypatite characterizes the maturation phase, commonly
initiated 2–3 weeks after induction of the differentiation
process.7 Successful osteogenic differentiation in vitro is ac-
companied by the sequential expression of the functional
matrix proteins collagen type I, osteopontin, and osteocal-
cin.4,6 Collagen type I is secreted during the initiation
phase of the differentiation process and is an essential part
of the final mineralized ECM.6 Osteopontin, an intermediate
stage marker expressed by immature osteoblasts, is believed
to have functions in the stabilization of the matrix, whereas
osteocalcin, a late-stage osteogenesis marker, may partici-
pate in the final mineralization of the ECM.6 Bone is a com-
plex tissue defined by constant turnover and remodeling in
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response to environmental and endogenous stimuli.8 In addi-
tion to maintaining the rigid structure of the skeletal system
to allow movement and loading, bone needs to be both light
and flexible.9 The sophisticated and tightly controlled inter-
play of several cell types is the basis for the regulation of this
intricate process, providing appropriate cues for the mainte-
nance of bone structure, function, and remodeling.9
The chitinase-like protein YKL-40 (CHI3L1, HCgp39) is
a secreted, 40-kDa mammalian glycoprotein, expressed by
articular chondrocytes, differentiated macrophages, synovio-
cytes, and osteoblasts.10,11 In vivo biological function re-
mains controversial, but crystallographic analysis shows
that binding of a putative ligand can induce conforma-
tional changes in the protein, indicating a potential signaling
role.12 Upregulation of YKL-40 in several inflammatory and
degenerative diseases (e.g., rheumatoid arthritis, osteoarthri-
tis, and certain cancers) implies that YKL-40 in particular
might prevent damage to the ECM by reducing the deleteri-
ous effects of proinflammatory cytokines.13,14 Furthermore,
since YKL-40 is expressed in normal bone marrow, a con-
nection between the host response to inflammation and the
process of tissue repair seems plausible.15,16
Interleukin (IL)-6 belongs to the gp130 cytokine family of
receptor subunit signal transducers and is generally consid-
ered an acute phase protein with pleiotropic activity.17,18
The physiological role of IL-6 is manifold, ranging from im-
munoregulation and participation in hematopoiesis, to the
regulation of bone turnover and angiogenesis.18 The IL-6–
mediated in vivo effects on bone homeostasis are generally
considered to be shifted towards bone resorption rather
than bone formation. Since the bone environment is naturally
rich in IL-6, mesenchymal precursor cells are known to ex-
press low levels of IL-6 receptor, which is essential for
IL-6 signal transduction. MSC-derived osteoblast precur-
sor cells are believed to either gain expression of IL-6 re-
ceptor during homing to sites of bone remodeling or may
require the presence of soluble IL-6 receptor for complete
activation.17
We have recently showed that low levels of lipopolysac-
charide (10 ng/mL) improve osteogenesis, increase cytokine
secretion (especially IL-6), and strongly promote YKL-40
gene expression and protein secretion.11 In the present
study, we determined whether recombinant human (rh)
IL-6 (5 ng/mL) may be responsible for the effects seen on os-
teogenic differentiation and YKL-40 expression in human,
bone marrow–derived MSCs.
Materials and Methods
Cell culture and proliferation
Cell culture experiments were carried out with human,
bone marrow–derived MSCs (Lonza, Basel, Switzerland)
in Dulbecco’s modified Eagle’s medium/F12 media (Gibco/
Life Technologies, Carlsbad, CA) supplemented with peni-
cillin/streptomycin (Invitrogen/Life Technologies, Carlsbad,
CA) and 10% MSC-approved fetal calf serum (Stemcell
Technologies, Vancouver, Canada) at 37C, 5% CO2, and
95% humidity. To induce osteogenic differentiation, basal
expansion media was switched to Differentiation Basal
Medium Osteogenic (Lonza) supplemented with dexametha-
sone, ascorbate, L-glutamine, streptomycin/penicillin, b-
glycerophosphate, and MSC growth supplement, and 4000
cells/cm2 were seeded. Three independent donors were
used to determine the effect of the continuous presence of
5 ng/mL rhIL-6 (ORF Genetics, Kopavogur, Iceland) in the
culture media on osteogenic differentiation of human
(h)MSCs. Proliferation and viability were assessed with
MTT proliferation assay (LGC Standards AB, ATCC Bio-
products, Boras, Sweden) following standard protocols.
Analysis of gene expression
RNA isolation was performed using Qiagen BioRobot
workstation (Qiagen, Hilden, Germany) and the EZ-1 RNA
Cell Mini Kit (Qiagen) following manufacturer’s instructions.
Samples were homogenized in a FastPrep 24-instrument (MP
Biomedicals, Santa Ana, CA) using Lysing Matrix D tubes
(MP Biomedicals) containing 1.4-mm ceramic spheres be-
fore RNA isolation. High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems/Life Technologies,
Carlsbad, CA) was used for transcription of RNA with a
master mix containing 2.0 lL of reverse transcription (RT)
buffer, 0.8 lL of 25 ·dNTP (100mM), 2.0 lL of 10 ·Ran-
dom Primers RT, 1.0 lL of Multiscribe reverse transcriptase,
1.0 lL of RNase inhibitor, and 3.2 lL of nuclease-free H2O
per sample. Cycling conditions were as following: 25C
for 10min, 37C for 120min, 85C for 5 sec, and then 4C.
Samples were stored at 20C before quantitative polymer-
ase chain reaction (qPCR) analysis.
Gene expression of selected genes was quantified using
the 7500 Real Time PCR System (Applied Biosystems).
Ten microliters of ready-made Taqman master mix (Applied
Biosystems), 1 lL of Taqman assay (Applied Biosystems),
and 9 lL of 1:10 diluted sample cDNA were prepared per
sample. Samples were analyzed at least in duplicate for
each of the three donors. Taqman assays used during this
study were: YKL-40 (Hs00609691_m1), COL1A2 (collagen
type I; Hs01028970_m1), ALP (alkaline phosphatase;
Hs01029141_g1), and RUNX-2 (runt-related transcription
factor 2; Hs00231692_m1). Data analysis of qPCR results
was performed using GenEX 5.3.2.13 software (MultiD,
Go¨teborg, Sweden). Missing data were handled with RT-
PCR replicates and outliers determined and deleted using
Grubb’s test. Gene expression results were globally normal-
ized with a cut-off at Ct = 34. In the next step, technical re-
peats were averaged and relative quantities were calculated
from the average of control samples from three independent
donors. The logarithm was taken and different data sets were
prepared for Ct values, mean centering, and auto-scaling of
samples, and after transposition as well to analyze the genes.
Validation of osteogenic differentiation
To determine ALP activity, cell lysates were incubated for
30min in a solution of 1mg/mL p-nitrophenyl phosphate in
0.2M Tris buffer (Sigma Aldrich Inc., St. Louis, MO) in dis-
tilled water (dH2O) at 37C. Optical density was measured at
405 nm in a MultiSkan spectrum spectrometer. Alkaline
phosphatase activity was calculated as nanomoles of p-nitro-
phenol per minute following the general Beer-Lambert law.
For specific staining of calcification during osteogenic dif-
ferentiation, medium was removed and cell layers washed
with phosphate-buffered saline (PBS) and then fixed in 4%
paraformaldehyde. Next, cells were washed with dH2O and
then stained with a 2% Alizarin Red solution (Sigma Aldrich
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Inc.) in dH2O at pH 4.1 for 20min. Cell layers were then
washed with dH2O, and pictures were taken in an inverted
microscope (Leica DM IRB, Leica Microsystems, Wetzlar,
Germany) with Infinity Capture 5.0.2 software. For quantifi-
cation, stained and dried cell layers were hydrated overnight
in dH2O, then incubated in a 10 % cetyl-pyridinium chloride
(Sigma Aldrich Inc.) solution in dH2O; optical density was
measured at 562 nm in a MultiSkan spectrum spectrometer.
To validate Alizarin Red staining of calcification, von
Kossa staining of mineralization was performed. Cells
were washed with PBS and fixed in 4% paraformaldehyde.
Standard protocols were used for von Kossa staining and im-
ages were taken in a fluorescent microscope (Olympus
BX51, Olympus, Center Valley, PA) using Cell A Imaging
Software (Olympus).
Polystyrene beads cytokine assay
Secretion of eight cytokines into medium supernatants
was detected using a custom-designed Luminex 8Plex
Human Cytokine assay (Panomics/Affymetrix, Santa Clara,
CA) with a detection limit of 1 pg/mL. Supernatant aliquots
were stored at 80C and were analyzed in duplicate. The
assay was performed according to manufacturer’s instruc-
tions. Cytokines determined were IL-1b, IL-4, IL-6, IL-8,
IL-10, IL-12p(40), RANTES, and tumor necrosis factor
(TNF)-a.
YKL-40 enzyme-linked immunosorbent assay
Levels of YKL-40 in the media supernatants of cells after
21 days of osteogenic differentiation were determined using
a sandwich enzyme-linked immunosorbent assay (ELISA;
MicroVue YKL-40, Quidel, San Diego, CA) with a detection
limit of 5.4 ng/mL. Supernatant aliquots were stored at
80C and were analyzed in duplicates. ELISA was per-
formed according to manufacturer’s instructions and concen-
tration of YKL-40 determined from a standard curve as
nanograms per milliliter.
Statistical analysis
Data are presented as mean plus or minus standard error.
Statistical analysis was performed using Prism 5.01 soft-
ware (GraphPad Software Inc., San Diego, CA) and for
qPCR analysis using GenEx 5.3.2.13 software. T-test was
used to evaluate the effect of IL-6 during osteogenic dif-
ferentiation of hMSCs; p < 0.05 was considered statisti-
cally significant. Three independent donors were used in
all experiments.
Results
Proliferation
The presence of rhIL-6 (5 ng/mL) during short-term (sin-
gle passage) expansion of hMSCs did not result in any
changes in attachment, cell morphology, or proliferation
(Fig. 1). Cells grew with typical spindle-shaped morphology
and proliferation followed a latent exponential growth curve,
as traditionally observed for this cell type.19 During osteogenic
differentiation, morphological changes in cell shape were ob-
served and calcium hydroxyapatite crystals were deposited.
The rhIL-6 did not affect osteoblastic cell morphology, yet a
visual increase in collagen deposition could be observed, caus-
ing the contraction of cell layers and finally detachment of the
complete cell sheet after 24 days in culture (visual observa-
tions, data not shown).
Osteogenic gene expression
The presence of rhIL-6 did not significantly alter the ex-
pression of any of the genes studied (Fig. 2). The lack of sig-
nificance during statistical analysis is due to the very high
standard error introduced by the use of three independent
donors, resulting in donor variation. In comparison to the
control group, rhIL-6 stimulation increased the expression
of ALP by 12.60– 11.75 fold, the expression of RUNX-2
by 2.51– 1.95 fold, and the expression of COL1A2 by 13.74–
12.73 fold, respectively.
FIG. 1. Proliferation of human mesenchymal stem cells
(hMSCs) during short-term expansion. Proliferation was de-
termined using MTT proliferation assay at days 1, 3, 5, and 7.
Error bars are standard error (n = 15).
FIG. 2. Effect of recombinant human interleukin (rhIL)-6
on osteogenic gene expression. Expression of alkaline phos-
phatase (ALP), runt-related transcription factor 2 (RUNX-2),
and collagen I (COL1A2), determined after 21 days of oste-
ogenic differentiation. Error bars are standard errors (n= 6).
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Validation of osteogenic differentiation
After 18 days of osteogenic differentiation, the activity of
ALP was not statistically different between control samples
(2.42 – 0.71) and rhIL-6–stimulated samples (2.73 – 0.40)
(Fig. 3A). The deposition of calcium hydroxyapatite crystals
was determined by von Kossa staining and Alizarin Red
staining, with the latter being specific for calcification and
quantifiable with the aid of cetyl-pyridinium chloride. Visual
examination of von Kossa stainings showed dark brown de-
posits, in the presence of rhIL-6, which were indicative of
mineralization, whereas no signs of mineralization were ob-
served in the control samples after 21 days of osteogenic dif-
ferentiation (Fig. 3B). The equivalent staining by Alizarin
Red strongly visualized the effects of donor variation on
the deposition of calcium hydroxyapatite (Fig. 3C). One
donor showed minimal calcification in the control samples,
while the presence of rhIL-6 was accompanied by the com-
plete absence of calcium-induced retention of the Alizarin
Red stain (Fig. 3C, upper panel). A second donor displayed
stronger overall calcification, with an increased number of
calcified modules in the presence of rhIL-6 (Fig. 3C, lower
panel). The quantitation of the staining in the two previously
mentioned donors compensated for the donor variation and
ultimately showed no difference in the calcification state be-
tween the control samples (0.1135– 0.003) and IL-6–stimu-
lated samples (0.1299 – 0.011; Fig. 3D).
Cytokine secretion into media supernatants
The secretion of several pro- and anti-inflammatory cyto-
kines was determined after 20 days of osteogenic differentiation
to evaluate whether the presence of rhIL-6 affected overall cy-
tokine secretion into media supernatants. No secretion of IL-1b,
IL-10, or RANTES was observed in control cells or rhIL-6–
stimulated cells. Minimal secretion of IL-4, IL-12p(40), and
TNF-a was seen, but no difference between the groups could
be identified (data not shown). As expected, the levels of IL-
6 in media supernatants were significantly higher in rhIL-6–
stimulated cultures (543.825–55.843 pg/mL in rhIL-6 samples
versus 7.990–0.418pg/mL in control samples; p<0.001; Fig.
4). The expression of the proinflammatory cytokine IL-8 was
high, both in control samples (104.082–2.904pg/mL) and
rhIL-6–stimulated samples (95.992–10.167 pg/mL), but no
statistical difference was observed.
YKL-40 gene expression and protein secretion
The effect of rhIL-6 on the chitinase-like protein YKL-40
was evaluated both on the gene and the protein level.
FIG. 3. Quality of osteogenic differentiation. (A) Alkaline phosphatase (ALP) activity at 18 days during osteogenic differ-
entiation. Error bars are standard errors (n = 3). (B) von Kossa Staining of mineral deposition during osteogenic differenti-
ation. Brown color depicts mineralization. Pictures are representative from three donors. (C) Alizarin Red staining of
calcification at 21 days of osteogenic differentiation. Red staining is specific for calcium deposition. Pictures of two indepen-
dent donors are shown to visualize donor variation in calcification. (D) Alizarin Red quantitation after 21 days of osteogenic
differentiation. Error bars are standard errors (n = 3).
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Following 21 days of osteogenic differentiation, no differ-
ence in the expression of the YKL-40 gene was observed be-
tween the groups (1.2 – 0.22 fold increase in rhIL-6 versus
control; Fig. 5A). However, the secretion of YKL-40 protein
was significantly higher in samples stimulated with rhIL-6
compared to control samples (24.43– 3.14 ng/mL in control
samples versus 40.40 – 3.70 ng/mL in rhIL-6 samples;
p < 0.01; Fig. 5B).
Discussion
In this study, we report the effect of rhIL-6 (5 ng/mL) on
expression and secretion of YKL-40, as well as on osteo-
genic differentiation of hMSCs. The proinflammatory cyto-
kine IL-6 is known for its role in bone turnover and
promoting committed osteoprogenitor cells towards differ-
entiation.17 The hMSCs used in the present study were de-
rived from the bone marrow environment, which is
naturally rich in IL-6.17 Therefore, the hypothesis that the
hMSC osteoblastic phenotype is influenced by the proinflam-
matory cytokine IL-6 has long been abolished.17,20 Here, we
confirm this notion by the absence of any statistically signif-
icant response during the evaluation of the quality of osteo-
genic differentiation. However, we were able to show a
donor-dependent increase in mineralization in the presence
of rhIL-6, accompanied by a significantly higher secretion
of YKL-40 protein after 21 days of osteogenesis.
In the presence of an osteogenic stimulus, hMSCs differ-
entiated along the osteogenic lineage, as judged by the ex-
pression of osteogenic marker genes and mineralization of
the ECM. rhIL-6 stimulation did not affect the quality of os-
teogenic differentiation, except for a nonsignificant increase
in collagen production (visual observation) and a donor-
dependent difference in calcification. Osteogenic differentia-
tion of bone marrow–derived hMSCs and murine MSCs was
previously shown to remain unaffected by rhIL-6 when sol-
uble IL-6 receptor was absent.17,21
We have recently shown that low amounts of lipopolysac-
charide can strongly promote osteogenic differentiation of
hMSCs as seen in increased marker gene expression, ALP
activity, and mineralization. This increase in differentiation
was accompanied by significantly increased cytokine secre-
tion, namely IL-6, IL-8, and RANTES, as well as higher
levels of YKL-40 gene expression and protein secretion.11
rhIL-6 has been linked to increased plasma YKL-40 levels
in a human model of sepsis.16 On the other hand, Recklies
et al.16 showed that rhIL-6 alone was not sufficient to in-
duce YKL-40 gene expression in a murine primary chondro-
cyte model. There was no mention of the concentration that
was applied, but their results correlate very well with ours
because we also did not see YKL-40 gene expression induced
by rhIL-6.16 However, we did see an increase in YKL-40
protein secretion after 21 days of osteogenic differentiation
in the presence of rhIL-6. It is possible that YKL-40 gene
expression was affected at intermediate stages during the dif-
ferentiation process because we only determined gene ex-
pression at the end of the differentiation period (21 days)
and the aforementioned study focused on early time points
(24 and 48 h)16. In addition, rhIL-6 may affect the posttrans-
lational regulation of YKL-40, independent of transcrip-
tional regulation of gene expression. This potential effect
of rhIL-6 on YKL-40 protein should be determined in further
studies.
Conclusion
In this study, we showed the effect of rhIL-6 on the expres-
sion of YKL-40 and the biology of osteogenic differentia-
tion of human, bone marrow–derived MSCs. rhIL-6 did
not affect the quality of osteogenic differentiation after 21
days in culture, yet a donor variation–dependent increase
FIG. 4. Effect of rhIL-6 on cytokine secretion during oste-
ogenic differentiation. Secretion of interleukin (IL)-6 and
IL-8 at 20 days of osteogenic differentiation. Error bars are
standard errors (n = 6); ***p < 0.001.
FIG. 5. Effect of rhIL-6 on the chitinase-like protein YKL-40. (A) Expression of YKL-40, determined after 21 days of os-
teogenic differentiation. Error bars are standard errors (n = 6). (B)YKL-40 protein secretion during osteogenic differentiation
of hMSCs. Error bars are standard errors (n = 6); **p < 0.01.
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in mineralization could be observed. The expression of
YKL-40 in the presence of rhIL-6 was comparable to con-
trol samples, whereas the secretion of YKL-40 protein
was significantly increased in three independent donors.
The determination of how rhIL-6 is involved in the posttran-
scriptional regulation of YKL-40 could aid in better under-
standing the physiological role of YKL-40 and narrow the
search for potential endogenous ligands.
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ALP¼ alkaline phosphatase
COL1¼ collagen type I
dH2O¼ distilled water
ECM¼ extracellular matrix
ELISA¼ enzyme-linked immunosorbent assay
hMSC¼ human mesenchymal stem cell
IL¼ interleukin
MSC¼mesenchymal stem cell
PBS¼ phosphate-buffered saline
qPCR¼ quantitative polymerase chain reaction
rh¼ recombinant human
RT¼ reverse transcription
RUNX-2¼ runt-related transcription factor 2
TNF¼ tumor necrosis factor
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